The use case: how Compugen deploys Nebius AI Cloud
Compugen, an Israeli biotech company, trained a model on Nebius AI Cloud GPUs that predicts tertiary lymphoid structures (TLS), a spatial immune feature linked to immunotherapy response, from single-cell expression data. The model is intended to be integrated into its Unigen drug target discovery platform.
In the customer’s words
Nebius gave us powerful GPUs, a smooth interface and competitive pricing to train large-scale models on sensitive biological data. It’s a great match for AI in biotechNebius AI Cloud users in IT Services & System Integration
Companies in the same sector, with public evidence.
See all Nebius AI Cloud customersGo straight to the source
Based on Nebius AI Cloud’s published case study. We check the public evidence; the results are reported by the vendor.
nebius.com- Last checked
- Nov 15, 2026
Open source capture What the story claims, and what we checked
What we compared with the page.
- The passage quoted aboveChecked
Copied word for word from the page, near the name of Compugen.
- Compugen uses Nebius AI CloudChecked
Confirmed line.
- The result itselfNot checked
We quote it; we did not measure it.
Starting as an educational partnership at Nebius Academy, the collaboration with Compugen quickly expanded into full‑scale training on Nebius AI Cloud, turning a classroom prototype into a production-grade research model that focuses on tertiary lymphoid structures (TLS)

